Johnson & Johnson (JNJ) has halved the number of Covid-19 vaccines; an E.U. official said it was scheduled to deliver the product this week, adding to the U.S. giant’s supply troubles. The U.S. giant began shipping the vaccines to Europe in April.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
According to its contract with the E.U., J&J is expected to deliver 55 million doses of its single-dose vaccine in the second quarter. So far, the company has delivered less than 5 million, or less than 10% of its original target.
An official of a European company involved in negotiations with the pharmaceutical sector told the European official that deliveries to companies are halved this week. The number of installments to be delivered next week is unknown, he said. It was not immediately clear how many would be delivered this week. In response to a request for comment, J&J did not respond.
“We understand that the reduction in deliveries is temporary and that it will be addressed at a later stage,” a spokesperson for the European Commission said. A representative of the company and the agency’s source shared that the company is committed to delivering the 55 million installments scheduled by the end of June.
American production for Johnson & Johnson (JNJ) wasn’t running smoothly. Officials with the E.U. said the doses bound for Europe were produced at a U.S. plant and Leiden, the Netherlands.
Despite original plans to start delivering to the European Union on April 1st, production issues delayed deliveries until about the middle of the month. After the vaccine was temporarily discontinued in the U.S. for safety reasons, deliveries were again suspended, pending an investigation into its possible link to rare thromboembolisms. A week later, deliveries to Europe resumed.
Based on data from the European Center for Disease Prevention and Control (ECDC), 2.6 million doses have been distributed to European countries. It has been reported that less than five million doses of the medicine have been delivered. The European Commission, which has the most up-to-date data on deliveries, has confirmed this.